$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000143774922011618 Filed on May 10, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$13.56M	$7.485M
YoY Change	81.22%
Cost Of Revenue	$1.525M	$897.0K
YoY Change	70.01%
Gross Profit	$12.04M	$6.588M
YoY Change	82.74%
Gross Profit Margin	88.76%	88.02%
Selling, General & Admin	$21.30M	$22.19M
YoY Change	-4.01%	0.98%
% of Gross Profit	176.92%	336.81%
Research & Development	$12.70M	$10.51M
YoY Change	20.76%	-36.62%
% of Gross Profit	105.46%	159.58%
Depreciation & Amortization	$200.0K	$200.0K
YoY Change	0.0%	100.0%
% of Gross Profit	1.66%	3.04%
Operating Expenses	$34.00M	$32.70M
YoY Change	3.96%	-15.19%
Operating Profit	-$21.96M	-$26.11M
YoY Change	-15.92%	-32.28%
Interest Expense	-$280.0K	$170.0K
YoY Change	-264.71%	-79.01%
% of Operating Profit
Other Income/Expense, Net	-$5.830M	$10.00K
YoY Change	-58400.0%	-125.0%
Pretax Income	-$28.07M	-$25.94M
YoY Change	8.22%	-31.37%
Income Tax	$325.0K	$0.00
% Of Pretax Income
Net Earnings	-$28.39M	-$25.94M
YoY Change	9.47%	-31.38%
Net Earnings / Revenue	-209.32%	-346.49%
Basic Earnings Per Share	-$1.25	-$1.17
Diluted Earnings Per Share	-$1.255M	-$1.166M
COMMON SHARES
Basic Shares Outstanding	22.63M	22.24M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$136.4M	$75.91M
YoY Change	79.75%	-36.26%
Cash & Equivalents	$105.4M	$40.49M
Short-Term Investments	$31.07M	$35.42M
Other Short-Term Assets	$9.825M	$7.500M
YoY Change	31.0%	167.86%
Inventory	$4.756M	$3.331M
Prepaid Expenses
Receivables	$9.499M	$6.301M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$160.5M	$93.08M
YoY Change	72.45%	-23.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.777M	$2.142M
YoY Change	-17.04%	116.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$674.0K	$0.00
YoY Change		-100.0%
Other Assets	$1.572M	$66.00K
YoY Change	2281.82%	-86.8%
Total Long-Term Assets	$5.191M	$4.332M
YoY Change	19.83%	-90.37%
TOTAL ASSETS
Total Short-Term Assets	$160.5M	$93.08M
Total Long-Term Assets	$5.191M	$4.332M
Total Assets	$165.7M	$97.41M
YoY Change	70.11%	-41.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.234M	$6.096M
YoY Change	-30.54%	46.82%
Accrued Expenses	$11.78M	$10.30M
YoY Change	14.35%	1.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.09M	$17.01M
YoY Change	12.27%	19.75%
LONG-TERM LIABILITIES
Long-Term Debt	$70.80M	$0.00
YoY Change
Other Long-Term Liabilities	$92.90M	$3.900M
YoY Change	2282.08%	69.57%
Total Long-Term Liabilities	$70.80M	$3.900M
YoY Change	1715.31%	69.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.09M	$17.01M
Total Long-Term Liabilities	$70.80M	$3.900M
Total Liabilities	$182.8M	$20.92M
YoY Change	773.63%	27.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$495.7M	-$382.4M
YoY Change	29.63%	43.87%
Common Stock	$478.7M	$458.8M
YoY Change	4.34%	10.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.07M	$76.49M
YoY Change
Total Liabilities & Shareholders Equity	$165.7M	$97.41M
YoY Change	70.11%	-41.64%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$28.39M	-$25.94M
YoY Change	9.47%	-31.38%
Depreciation, Depletion And Amortization	$200.0K	$200.0K
YoY Change	0.0%	100.0%
Cash From Operating Activities	-$24.00M	-$27.40M
YoY Change	-12.43%	-23.11%
INVESTING ACTIVITIES
Capital Expenditures	$25.00K	$287.0K
YoY Change	-91.29%	198.96%
Acquisitions
YoY Change
Other Investing Activities	$13.62M	$15.31M
YoY Change	-11.03%	16.69%
Cash From Investing Activities	$13.60M	$15.02M
YoY Change	-9.5%	15.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$70.74M	$4.000K
YoY Change	1768450.0%	-95.56%
NET CHANGE
Cash From Operating Activities	-$24.00M	-$27.40M
Cash From Investing Activities	$13.60M	$15.02M
Cash From Financing Activities	$70.74M	$4.000K
Net Change In Cash	$60.34M	-$12.37M
YoY Change	-587.69%	-45.06%
FREE CASH FLOW
Cash From Operating Activities	-$24.00M	-$27.40M
Capital Expenditures	$25.00K	$287.0K
Free Cash Flow	-$24.02M	-$27.69M
YoY Change	-13.24%	-22.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	75000000	USD
CY2022Q1	urgn	Debt Instrument Capitalized Costs And Discounts DebtInstrumentCapitalizedCostsAndDiscounts	4169000	USD
CY2022Q1	urgn	Debt Instrument Paid And Payable Amount DebtInstrumentPaidAndPayableAmount	316000	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22693170
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22682221
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22682221
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22462995
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22462995
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-25935000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-25935000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-17074000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-128000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-25935000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	76491000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28392000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-25935000	USD
CY2020Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	75000000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M10D
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M17D
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	841000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1257000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1207000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	182000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	243000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	251000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	49000	USD
CY2021Q1	urgn	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	725000	USD
CY2021Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1708000	USD
CY2022Q1	urgn	Sales Reserve Utilization SalesReserveUtilization	-2412000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105379000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44360000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	31065000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44779000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	550000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9499000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11717000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	4756000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4832000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9275000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7476000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	160524000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	114390000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1777000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	USD
CY2022Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	USD
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	945000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	674000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	675000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1572000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1311000	USD
CY2022Q1	us-gaap	Assets Assets	165715000	USD
CY2021Q4	us-gaap	Assets Assets	119746000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9936000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5146000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6948000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4009000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3330000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19091000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22380000	USD
CY2022Q1	urgn	Prepaid Forward Obligation PrepaidForwardObligation	89782000	USD
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	70797000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	277000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	USD
CY2022Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	USD
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	182789000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	111333000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	61000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	478646000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475698000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-495713000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467321000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-69000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-17074000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165715000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119746000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13564000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7485000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1525000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	897000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	12039000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	6588000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12696000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10513000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21300000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22189000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21957000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26114000	USD
CY2022Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5826000	USD
CY2021Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	-0	USD
CY2022Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	282000	USD
CY2022Q1	urgn	Other Income Expense OtherIncomeExpense	-2000	USD
CY2021Q1	urgn	Other Income Expense OtherIncomeExpense	179000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28067000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25935000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	325000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-44000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-128000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28436000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26063000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22631509
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22242375
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2949000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6195000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	215000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	191000	USD
CY2022Q1	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	4289000	USD
CY2021Q1	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	0	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-50000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-191000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2949000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6195000	USD
CY2022Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	282000	USD
CY2021Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	0	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	241000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	237000	USD
CY2022Q1	urgn	Operating Lease Liability Noncash Adjustments OperatingLeaseLiabilityNoncashAdjustments	286000	USD
CY2021Q1	urgn	Operating Lease Liability Noncash Adjustments OperatingLeaseLiabilityNoncashAdjustments	400000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-76000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1367000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2218000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-746000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1800000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2952000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	169000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-0	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2169000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	535000	USD
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1801000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4842000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	301000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23996000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27401000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13621000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	15311000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	287000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13596000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15024000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	70831000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70742000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	60342000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12373000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45587000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	105929000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41717000	USD
CY2022Q1	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	6000	USD
CY2021Q1	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	-20000	USD
CY2022Q1	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	3000	USD
CY2021Q1	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
CY2022Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> as filed with the Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 21, 2022.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $495.7</span> million and $467.3 million as of <em style="font: inherit;"> March 31, 2022</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next <em style="font: inherit;">12</em> months. The Company anticipates that it will need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p>
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-495700000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467300000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	137100000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4234000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5786000	USD
CY2022Q1	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	361000	USD
CY2021Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	497000	USD
CY2022Q1	urgn	Accrued Clinical Expense AccruedClinicalExpense	1129000	USD
CY2021Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1377000	USD
CY2022Q1	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1186000	USD
CY2021Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1748000	USD
CY2022Q1	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2042000	USD
CY2021Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1965000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	984000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	729000	USD
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9936000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	167000	USD
CY2022Q1	urgn	Other Finance Income Expense OtherFinanceIncomeExpense	-4000	USD
CY2021Q1	urgn	Other Finance Income Expense OtherFinanceIncomeExpense	12000	USD
CY2022Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	-2000	USD
CY2021Q1	urgn	Interest And Other Income Net InterestAndOtherIncomeNet	179000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3663000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3894000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2365000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1958000	USD
CY2022Q1	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6028000	USD
CY2021Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	5852000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	31808000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	69000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	31739000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	100000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	31700000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	31065000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44779000	USD
CY2022Q1	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	674000	USD
CY2021Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	675000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	31739000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	45454000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4218000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4193000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2441000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2226000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1777000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2021	urgn	Capitalized Closing Costs On Prepaid Forward Obligation CapitalizedClosingCostsOnPrepaidForwardObligation	2599000	USD
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17291000	USD
CY2021	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	3979000	USD
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	USD
CY2022Q1	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	5826000	USD
CY2022Q1	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	1757000	USD
CY2022Q1	urgn	Prepaid Forward Obligation PrepaidForwardObligation	89782000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	259000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	267000	USD
CY2022Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	282000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	70797000	USD
CY2020Q4	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	200000	USD
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	17000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	22000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	220000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	233000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	945000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	277000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3322000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2157000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	144000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	135000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578	pure
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0536	pure
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	358000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	58000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	50000	USD
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	56000	USD
CY2022Q1	urgn	Sales Reserve Accruals SalesReserveAccruals	2093000	USD
CY2022Q1	urgn	Accrued Sales Reserve AccruedSalesReserve	1389000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22700000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22500000
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3949544
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	722810
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2949000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6195000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	900000	USD

Files In Submission

Name	View Source	Status
0001437749-22-011618-index-headers.html	Edgar Link	pending
0001437749-22-011618-index.html	Edgar Link	pending
0001437749-22-011618.txt	Edgar Link	pending
0001437749-22-011618-xbrl.zip	Edgar Link	pending
ex_355349.htm	Edgar Link	pending
ex_355350.htm	Edgar Link	pending
ex_355351.htm	Edgar Link	pending
ex_355352.htm	Edgar Link	pending
ex_371898.htm	Edgar Link	pending
ex_372863.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20220331.xsd	Edgar Link	pending
urgn-20220331_cal.xml	Edgar Link	unprocessable
urgn-20220331_def.xml	Edgar Link	unprocessable
urgn-20220331_lab.xml	Edgar Link	unprocessable
urgn-20220331_pre.xml	Edgar Link	unprocessable
urgn20220331_10q.htm	Edgar Link	pending
urgn20220331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2022 Q1 Form 10-Q Financial Statement

#000143774922011618 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2022 Q1 Form 10-Q Financial Statement

#000143774922011618 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn